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Abstract
This chapter is a review of the most common radiotracers currently used in clinical brain
tumour imaging, and an update of future potentially useful radiotracers for imaging
brain tumours with positron emission tomography (PET). It will focus mainly on glioma
—the most common type of primary brain tumour—and intracranial metastases, as the
cause of the majority of morbidity and mortality in neurooncology. Emerging data
support the use of somatostatin analogue PET in the treatment planning and surveil‐
lance of meningiomas. There is currently a limited role of PET in other non-glial brain
neoplasms  including  neuronal  tumours,  pineal  and  pituitary  tumours,  germ  cell
tumours and embryonal tumours (PNET, neuroblastoma). Finally, the newest hybrid
imaging modality of PET/MRI and the promise it holds for obtaining state-of-the-art
structural and functional imaging data simultaneously, are concisely reviewed.
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1. Introduction
Structural  imaging  using  contrast-enhanced  computed  tomography  (CT)  and  magnetic
resonance imaging (MRI) is crucial for the initial detection and diagnosis of brain tumours.
However, it has limitations in post-treatment surveillance where tumour- and therapy-related
changes can appear similarly. Molecular imaging with positron emission tomography (PET)
provides additional information that can better delineate tumour extent and burden, for example
fluorodeoxyglucose (FDG) depicts the metabolic activity and fluroethyltyrosine (FET) and
fluorodihydroxyphenylalanine (FDOPA) depict the amino acid turnover of otherwise nonspe‐
cific soft tissue changes on CT and MRI. This could ultimately improve clinical decision-making
and anatomical targeting of tumour for biopsy, radiotherapy or surgery.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Brain tumour types
Brain tumours affect approximately 5–10 persons per 100,000 populations. In adults, about
half of all brain neoplasms are primary tumours and the other half are metastatic. In child‐
hood, brain neoplasms account for up to 20% of all cancers. Seventy percentage of childhood
brain tumours arise from the posterior cranial fossa, whereas in adults, a similar proportion
arises above the tentorium [1].
Intracranial tumours may spread directly to adjacent structures, along white matter tracts, or
through the cerebrospinal fluid (CSF) spaces. It is rare for brain malignancy to metastasise to
other parts of the body.
The most widely accepted system for classifying brain tumours is the World Health
Organisation (WHO) classification of tumours of the central nervous system (CNS), which is
based on the histological characteristics of the tumour. The latest revision was published in
2007 [2].
2.1. Gliomas
Gliomas are tumours of glial cells and include astrocytomas, oligodendrogliomas and epen‐
dymomas. Unlike most neurons, glial cells retain the ability to undergo cell division in the
adult CNS. Since carcinogenesis is related to the sequential accumulation of genetic aberra‐
tions through cell division, it is not surprising that gliomas are the most common primary
brain malignancy and account for about half of all adult brain tumours. The WHO classifica‐
tion of CNS tumours additionally classifies gliomas into Grade I to IV depending on the
degree of tumour histological differentiation (Table 1).
I   II   III   IV   I   II   III   IV  
 Astrocytic tumours
 Subependymal giant cell astrocytoma • Central neurocytoma •
 Pilocytic astrocytoma • Extraventricular neurocytoma •
 Pilomyxoid astrocytoma • Cerebellar liponeurocytoma •
 Diffuse astrocytoma • Paraganglioma of the spinal cord •
 Pleomorphic xanthoastrocytoma • Papillary glioneuronal tumour •
 Anaplastic astrocytoma • Rosette-forming glioneuronal tumour of the fourth ventricle  •
 Glioblastoma •
 Giant cell glioblastoma •
 Gliosarcoma • Pineal tumours
Pineocytoma •
 Oligodendroglial tumours Pineal parenchymal tumour of intermediate differentiation • •
 Oligodendroglioma • Pineoblastoma •
 Anaplastic oligodendroglioma • Papillary tumour of the pineal region • •
 Oligoastrocytic tumours
 Oligoastrocytoma • Embryonal tumours
 Anaplastic oligoastrocytoma • Medulloblastoma •
CNS primitive neuroectodermal tumour (PNET) •
 Ependymal tumours Atypical teratoid / rhabdoid tumour •
 Subependymoma •
 Myxopapillary ependymoma • Tumours of the cranial and paraspinal nerves
 Ependymoma • Schwannoma •
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I   II   III   IV   I   II   III   IV  
 Anaplastic ependymoma • Neurofibroma •
Perineurioma • • •
 Choroid plexus tumours Malignant peripheral nerve sheath tumour (MPNST) • • •
 Choroid plexus papilloma •
 Atypical choroid plexus papilloma • Meningeal tumours
 Choroid plexus carcinoma • Meningioma •
Atypical meningioma •
 Other neuroepithelial tumours Anaplastic/malignant meningioma •
 Angiocentric glioma • Haemangiopericytoma •
 Chordoid glioma of the third ventricle • Anaplastic haemangiopericytoma •
Haemangioblastoma •
 Neuronal and mixed neuronal-glial tumours
 Gangliocytoma • Tumours of the sellar region
 Ganglioglioma • Craniopharyngioma •
 Anaplastic ganglioglioma • Granular cell tumour of the neurohypophysis •
 Desmoplastic infantile astrocytoma and
   ganglioglioma
• Pituicytoma •
 Dysembryoplastic neuroepithelial tumour • Spindle cell oncocytoma of the adenohypophysis •
Table 1. WHO grading of tumours of the CNS.
2.2. Brain metastases
The most common primary malignancies that metastasise to the brain are carcinomas of the
lung, breast and melanoma [3]. The meninges are also a frequent site of metastatic disease
involvement.
The following sections on molecular imaging with PET radiotracers will focus on gliomas and
intracranial metastases as the cause of the majority of morbidity and mortality in neurooncol‐
ogy.
3. Fluorodeoxyglucose
3.1. Tumour detection
F-18 FDG is an analogue of glucose (Figure 1). Its active transport into the cell is mediated by
a group of structurally related glucose transport proteins (GLUT) and once intracellular, FDG
Figure 1. Chemical structure of F-18 fluorodeoxyglucose.
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is phosphorylated by the enzyme hexokinase as the first step towards glycolysis. However,
unlike glucose, once phosphorylated FDG-6-phosphate cannot continue along the glycolytic
pathway and effectively becomes trapped intracellularly. FDG uptake in PET is thus an
indication of the metabolic activity of the structure in which it is being taken up. Most
malignant cells are metabolically active and demonstrate an increased expression of glucose
transport proteins, particularly GLUT-1 and GLUT-3, as well as higher levels of hexokinase.
FDG is the single most important, widely used and explored radiotracer in PET; however, its
current role in brain tumour imaging is limited due to the presence of intense physiological
FDG uptake in the normal brain resulting in poor tumour-to-background contrast. Thus, an
underlying brain tumour, even if FDG-avid, can escape detection on FDG PET (Figure 2). In
some studies, increased FDG uptake in gliomas was only reported in 21–47% of high-grade
tumours and as few as 3–6% of low-grade tumours [4, 5]. Delayed imaging (e.g. 6 h) follow‐
ing FDG administration instead of the usual imaging performed 60–90 min post-radiotracer
can improve discrimination between tumour and physiological background uptake as FDG is
retained in tumour longer than in normal brain parenchyma [6].
Figure 2. FDG uptake in a left frontal cerebral glioma on PET/CT. Top row: The tumour is not readily discernible from
intense physiological FDG activity in the adjacent cerebral parenchyma. Bottom row: The tumour is much better depict‐
ed on MRI FLAIR imaging (bottom left panel) and shows no contrast enhancement due to its low grade (bottom right
panel).
Neurooncology - Newer Developments186
3.2. Tumour grading and prognosis
The uptake of FDG in a neoplasm is a consequence of the increased expression and activity of
glucose transporter proteins and of hexokinase, a glucose phosphorylating enzyme. FDG
uptake generally correlates with tumour grade [7–9], with low-grade tumours showing similar
FDG uptake as white matter, and high-grade tumours similar uptake as grey matter. Tumours
can be heterogeneous and contain areas of low- and high-grade dedifferentiation.
FDG uptake in gliomas has also been shown to correlate with survival [10, 11]. Median survival
for intracranial metastases is typically less than 1 year, with these metastases generally
showing a high-grade pattern of FDG uptake.
3.3. Localisation for biopsy
FDG PET can be useful in selection of a biopsy site where uptake is highest in the tumour,
thereby ensuring sampling of the most malignant tissue [12–16].
3.4. Radiotherapy planning
MRI is the current technique of choice for radiotherapy planning. Due to its relatively low
tumour-to-background contrast, FDG PET has limited utility for conventional treatment
planning. More recently, the addition of PET imaging of some radiotracers—in particular the
amino acid analogues—in radiotherapy planning has been shown to be promising in the
identification of microscopic residual tumour post-surgery and differentiation of tumour from
brain tissue, thereby improving local control and reducing radiation to healthy brain paren‐
chyma (see Section 4).
3.5. Assessment of treatment response
The differentiation of tumour recurrence from radiation necrosis following treatment is one
of the most common and important clinical indications for MRI and PET. Both viable tu‐
mour and post-radiotherapy necrosis demonstrate contrast enhancement on MRI. Similarly,
increased FDG uptake cannot reliably differentiate residual/recurrent tumour from radiation
necrosis. Furthermore, false-negative MRI and FDG PET can result from decreased enhance‐
ment (due to antiangiogenic therapy) and poor tumour-to-background contrast, respectively.
Whilst the criteria for Response Assessment in Neuro-Oncology have been updated to mitigate
these potentially confounding factors in MRI [17–19], advancements in response assessment
in PET have focused on other (non-metabolic) radiotracers.
4. Amino acid radiotracers
Amino acids are the building blocks of proteins and critical to nearly every biological process
in the human body. They serve as components in metabolic cycles which are upregulated in
cancer cells with increased proliferative activity. Because the brain uses glucose almost
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exclusively for fuel (except during prolonged starvation), PET imaging of brain tumours with
amino acid and amino acid analogue radiotracers has a significant advantage of high tu‐
mour-to-background contrast (Figure 3).
Figure 3. F-18 FDG PET/CT (top row) and F-18 FDOPA PET/CT (bottom row) of a left frontotemporal low-grade non-
enhancing cerebral glioma showing the high tumour-to-background contrast of amino acid imaging compared with
metabolic imaging.
4.1. Methionine
Methionine (MET) is a sulphur-containing naturally occurring amino acid (Figure 4) whose
transport into malignant glioma cells and the supporting vasculature of these tumours is
strongly upregulated [20–22].
Figure 4. Chemical structure of methionine.
C-11 MET is one of the most widely used amino acid radiotracers for PET imaging in neuro‐
oncology, mainly due to its relative ease of production that can be performed rapidly with
high yield and without the need for complicated purification steps.
The overall sensitivity of MET PET for malignant gliomas ranges from 76 to 95%, with higher
rates of detection for higher grade tumours [23]. Increased uptake of MET is also seen in low-
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grade gliomas—with reported sensitivities of 65–85% [23, 24]—in which there is typically little
or absent contrast enhancement on MRI and low uptake on FDG PET [24, 25].
MET is also generally regarded as the reference in prognostication of disease, image-guided
biopsy and radiotherapy planning, and the detection of tumour recurrence [26–34], making it
the most important radiotracer in the amino acid category.
The main limitation of C-11 MET is its short half-life (20 min), confining its use to centres with
a cyclotron on-site or very nearby. It has also been shown to accumulate in brain abscesses and
inflammation (cerebritis) [35], important false positives to exclude in the diagnosis of brain
tumour.
F-18 has a much longer half-life (110 min) than C-11 and opens up the possibility of radiotrac‐
er transport to another centre for diagnostic imaging. F-18 labelled amino acids include F-18-
labelled fluoroethyltyrosine (FET) and dihydroxyfluorophenylalanine (FDOPA).
4.2. Fluoroethyltyrosine
FET is an artificial amino acid (Figure 5) taken up by upregulated tumour cells but not
incorporated into proteins (unlike naturally occurring amino acids such as methionine). As
such, its use in the characterisation of brain lesions and the grading of gliomas requires
dynamic analysis of activity over time [36]. Its overall accuracy in the diagnosis of gliomas is
comparable to MET [37, 38]. It is an excellent tool for differentiating tumour from non-tumour
causes in the initial evaluation of newly diagnosed brain lesions [39] (Figure 6). FET PET can
also distinguish active tumour from radiation necrosis following treatment [40, 41].
Figure 5. Chemical structure of F-18 fluoroethyltyrosine.
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Figure 6. FET PET/CT (left-sided panels) and pre/post intravenous gadolinium MRI (right-sided panels) in a patient with
two small cerebral melanoma metastases (red and blue arrows).
4.3. Fluorodihydroxyphenylalanine
FDOPA was originally developed for imaging the DOPA-decarboxylase pathway in
Parkinson’s disease and other neurodegenerative diseases. It is a fluorinated form of L-
DOPA (Figure 7) which is used to increased dopamine concentrations in the treatment of
Parkinson’s disease. FDOPA has since been shown to be a marker of amino acid transport in
brain tumours and metastases.
Figure 7. Chemical structure of F-18 fluorodihydroxyphenylalanine.
FDOPA uptake has been shown to correlate with tumour proliferation and grade [42], and
more accurate than FDG for evaluating low-grade tumours and distinguishing tumour
recurrence from radiation necrosis [43].
It also accumulates in neuroendocrine tumours (NETs) such as phaeochromocytomas and
paragangliomas.
5. Fluorothymidine
Thymidine (T) is the pyrimidine deoxynucleoside in DNA that pairs with deoxyadenosine (A).
F-18 fluorothymidine (FLT) is a thymidine analogue (Figure 8) and a substrate for thymi‐
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dine kinase 1 (responsible for synchronising cells in G1/early S phase), but unlike thymidine,
FLT is a poor substrate for mitochondrial thymidine kinase 2 and its uptake is therefore specific
to the cell cycle and a marker of cellular proliferation.
Figure 8. Chemical structure of F-18 fluorothymidine.
FLT uptake in normal brain cells is limited by the blood–brain barrier, thus FLT PET pro‐
vides higher tumour-to-background contrast than FDG PET. FLT is more sensitive than FDG
PET for the detection of recurrent high-grade glioma and also correlates better with tumour
progression and survival [44].
However, its use as a quantitative marker of the activity of DNA synthesis in gliomas remains
a subject of debate, particularly whether FLT can discriminate moderately proliferative
tumours driven by thymidine salvage pathway utilisation from highly proliferative tumours
primarily driven by de novo synthesis of thymidine. Quantitative FLT PET with kinetic
modelling may also be useful for distinguishing glioma recurrence from radiation necrosis [45].
6. Choline
Choline is a water-soluble B-complex vitamin (Figure 9), normally found in blood, which is
phosphorylated and subsequently integrated into lecithin, a component of cell membrane
phospholipids. Malignant tumour cells demonstrate increased proliferation which results in
increased cell membrane turnover and a greater demand for cell membrane components such
as choline.
Figure 9. Chemical structure of choline.
Like the amino acid radiotracers, PET imaging with choline offers excellent delineation of
tumour from brain with a 10:1 contrast ratio achievable within 5 min of radiotracer injection
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[46]. Higher choline uptake generally corresponds with more malignant tumours, and choline
PET also appears promising for radiotherapy planning because of more precise delineation of
biological target volume [47]. It also has higher accuracy than FDG PET and MRI for the
differentiating radiation necrosis and tumour recurrence [47].
Choline can be radiolabelled with C-11 or F-18, permitting its use in centres without an on-site
cyclotron.
It has also been investigated extensively for imaging in prostate cancer, with some studies also
suggesting a potential role in oesophageal and lung cancer [46, 48–50].
7. Hypoxia radiotracers
Hypoxia is an important factor in the malignant progression of tumour and its resistance to
therapy. The majority of hypoxia PET radiotracers belong to a group of compounds known as
nitroimidazoles that freely cross the blood–brain barrier, enter cells by diffusion and are
subsequently reduced by nitroreductases at a rate inversely proportional to oxygen tension.
Thus, in an oxygen-rich environment, they are able to diffuse back out of the cell again, whereas
under hypoxic conditions, they are reduced and become irreversibly trapped in the cell.
Another favourable property of the nitroimidazoles is their rapid equilibration within the brain
parenchyma independently of perfusion.
7.1. Fluoromisonidazole
F-18 fluoromisonidazole (FMISO) was the first of the nitroimidazole radiotracers (Figure 10)
to be developed for imaging with PET and has been widely used in preclinical and clinical
studies.
Figure 10. Nitroimidazoles are the most commonly used hypoxia PET radiotracers. FMISO: fluoromisonidazole; FA‐
ZA: fluoroazomycin; FETNIM: fluoroerythronitroimidazole.
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Hypoxia can be quantified by analysing FMISO PET images using a simple tissue-to-blood
ratio of radiotracer activity, with a ratio of 1.2 or greater useful for discriminating and
quantifying hypoxic tissue. Hypoxic tumour volume and maximal tumour-to-blood ratio
calculated in this way has been shown to predict worse prognosis independent of other
factors [51]. FMISO can also differentiate lower from higher grade gliomas better than FDG
[52].
More recently, an image-derived region to assess blood activity on FMISO PET has been shown
to be an accurate surrogate for serial blood sampling in the quantification of hypoxia [53] and
this may obviate the need for routine venous sampling in patients undergoing FMISO PET in
the future.
7.2. Fluoroazomycin
F-18 fluoroazomycin (FAZA) is a second-generation nitroimidazole derivative (Figure 10) with
more favourable pharmacokinetics than FMISO. FAZA demonstrates faster clearance of
unbound radiotracer from non-hypoxic areas (thereby resulting in shorter waiting time for
imaging) and improved biodistribution (does not cross the intact blood–brain barrier due to
its increased hydrophilicity). Consequently, there is improved hypoxia-to-normoxia contrast,
and FAZA shows considerable promise and is expected to overcome the disadvantages of
FMISO for imaging hypoxia in brain tumours.
8. Meningiomas
Meningiomas are predominantly benign tumours in adults arising from the meningotheli‐
um of the arachnoid mater. Consequently, they occur at the brain surface—over the cerebral
convexity, parafalcine region or along the skull base. Rarely, they can occur in intraventricu‐
lar or intraosseous locations. Meningiomas account for 20–25% of all intracranial neoplasms,
with women affected more commonly than men. They are commonly associated with loss of
heterozygosity of the long arm of chromosome 22.
On CT and MRI, meningiomas typically appear as rounded or ovoid avidly enhancing masses
with dural tails at the tumour margins, variable compressive effect on adjacent brain paren‐
chyma (mainly depending on tumour size) and occasional hyperostosis of the adjacent skull.
Molecular imaging of meningiomas can be accurately performed using somatostatin ana‐
logue radiotracers [54] (Figure 11).
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Figure 11. Row A: Fusion PET/CT shows a Ga-68 DOTATATE-avid focus directly adjacent to the right anterior clinoid
process of the sphenoid bone. Rows B and C: Multiplanar MRI sequences show characteristic features of an intracranial
meningioma on non-enhanced (arrows) and gadolinium-enhanced (arrowheads) imaging.
8.1. Somatostatin analogue radiotracers
Currently, the primary indication for using gallium-68 (Ga-68)-labelled somatostatin ana‐
logue radiotracers is for PET imaging of carcinoid and other NETs which usually express a
high density of somatostatin receptors to which these peptides bind with high affinity [55].
Some non-NETs are also known to express somatostatin receptors, including meningiomas
[56–58] which express all of the five somatostatin receptor (SSTR) subtypes but predominant‐
ly SSTR1 and SSTR2.
Traditional scintigraphic imaging of meningiomas utilised indium-111-labelled octreotide and
single-photon emission computed tomography (SPECT). However, PET imaging with Ga-68-
labelled somatostatin analogue radiotracers such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA)-Tyr3-octreotate (TATE), DOTA-1-Nal3-octreotide (NOC) and DOTA-
Phe1-Tyr3-octreotide (TOC) offers superior count statistics and spatial resolution compared
with SPECT. It also provides much higher target-to-background ratio of radiotracer uptake
and more detailed tumour characterisation and has largely replaced octreotide SPECT
imaging. This detailed spatial characterisation of meningiomas, when coupled with anatom‐
ical imaging by CT and MRI (in particular), allows for more accurate radiotherapy planning
in patients with large, non-resectable tumours.
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The demonstration of DOTATATE avidity in an intracranial lesion with only some features of
meningioma on CT or MRI could permit differentiation of a meningioma from other tu‐
mours such as metastasis or craniopharyngioma, which can have a significant impact on
clinical management.
There are also emerging data that DOTATATE uptake on PET improves diagnostic accuracy
by delineating meningioma from tumour-free tissue [58] that can potentially enhance on CT
and MRI especially in the setting of previous therapy.
FET PET in the late phase may be useful for the non-invasive grading of meningiomas [59].
9. Lymphoma
Almost all patients with primary CNS lymphoma have brain parenchymal lesions which have
a predilection for the periventricular and superficial regions. Contrast-enhanced MRI remains
the technique of choice when CNS lymphoma is suspected, although it is usually not possi‐
ble to conclusively differentiate CNS lymphoma from other malignant brain lesions on MRI.
FDG remains the most widely explored radiotracer for PET imaging in CNS lymphoma,
though its utility is limited compared with FDG PET in extracranial lymphoma, due to the
poor tumour-to-background contrast in the brain. FDG uptake is typically intense in lympho‐
ma—metabolic imaging with PET may help to differentiate lymphoma in the brain from low-
grade gliomas and meningiomas [60–62] and may also be suitable for early evaluation of post-
treatment response [60]. Infectious pathologies in the brain of immunocompromised subjects
can be discerned from lymphoma by their usually hypometabolic nature on FDG PET [63],
and high uptake ratio on thallium-201 (Tl-201) imaging [64]. Steroid treatment can cause false-
negative results by reducing FDG uptake in CNS lymphoma [62].
MET PET typically shows intense uptake in CNS lymphomas which often involves a larger
area than the corresponding enhancing abnormality on CT and MRI and may more accurate‐
ly delineate the actual tumour margins [65]. It may also be more accurate for the detection of
residual or recurrent lymphoma after treatment [65].
10. Other non-glial neoplasms
There is currently a limited role of PET in other non-glial brain neoplasms including neuro‐
nal tumours, pineal and pituitary tumours, germ cell tumours and embryonal tumours (PNET,
neuroblastoma), although anecdotal evidence, case reports and series exist for some of these
tumours.
PET imaging with MET, for example, detected all but one CNS germinoma in a case series of
10 patients [66], and choline uptake correlated with residual intracranial non-seminomatous
germ cell tumour in a series of four patients [67].
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Pituitary adenomas can appear as hypermetabolic lesions on FDG PET [68, 69], with higher
uptake seen in macroadenomas than in microadenomas [69]. Increased DOTATATE uptake
has been reported in intracranial metastases of pituitary carcinoma and may be useful in the
decision to treat with peptide receptor radionuclide therapy [70, 71]. MET successfully detected
all cases of craniopharyngioma in 10 patients [72].
11. PET/MRI
PET/MRI is a relatively novel hybrid diagnostic imaging device that can simultaneously
acquire PET and MR images of the brain and other body regions. PET images show the
distribution of an intravenously injected radiotracer, whilst MRI depicts the local responses of
atomic nuclei to high-frequency radio waves when placed in a strong magnetic field. PET/MRI
represents an advance on hybrid PET/CT imaging systems that are currently used in routine
clinical practice for the assessment of patients with cancer and other diseases.
The integration of PET with MRI rather than CT has several advantages:
a. Reduced radiation exposure for patients. The use of MRI to correct PET images for the
attenuation of emitted radiation by overlying tissue avoids the ionising radiation of CT.
Because the acquisition time for MRI often exceeds that for PET, there are also opportu‐
nities to reduce the amount of radiotracer administered, by increasing PET acquisition
time.
b. More accurate anatomical localisation of areas of radiotracer uptake. The simultane‐
ous acquisition of MR and PET images reduces the likelihood of patient movement
causing misregistration of the two image sets.
c. Compensation for some limitations of PET. The ability of PET to identify tumour sites is
constrained by background physiological tracer uptake in some organs. For the most
commonly used clinical PET radiotracer, FDG, these organs include the brain (as well as
the liver and bone marrow) which are frequent sites of tumour recurrence after initial
treatment. PET interpretation is also complicated by processes other than tumour
infiltration that can cause radiotracer uptake, the most notably inflammation which can
be particularly problematic when assessing cancer status after treatment, especially
surgery or radiotherapy.
Many of these advantages are particularly relevant to brain tumour imaging, and indeed, the
first exploration of feasibility of hybrid PET/MRI in clinical oncology was in brain tumours [73].
PET/MRI could theoretically harness the advantages of PET imaging with various radiotrac‐
ers to accurately distinguish tumours from surrounding normal brain tissues—and the ability
of advanced MRI techniques such as fMRI and diffusion tensor imaging to map the spatial
relationship between tumours and adjacent functional brain tissues and white matter tracts—
at the same time.
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To date, studies in PET/MRI have shown that it can diagnose, grade and evaluate treatment
response in glioma patients [74, 75]. Other studies have also shown that PET/MRI can identify
areas of greater cellular proliferation and vascularity in brain tumours using a combination of
advanced MRI techniques and PET radiotracers for treatment targeting [76–78]. FMISO
PET/MRI can quantify hypoxia in recurrent glioma for risk stratification prior to commence‐
ment of angiogenesis inhibitor therapy (such as bevacizumab) and assess response to
treatment [79, 80].
PET/MRI may gradually replace PET/CT in paediatric oncology due to the radiation dose
saving achieved with performing MRI in place of CT, and more specifically in the field of
neurooncology, the superior characterisation of brain tumours afforded by MRI over CT. In
this arena, PET/MRI with choline and FDOPA have shown promise in the imaging of paediatric
astrocytomas [81, 82].
The major disadvantages of PET/MRI currently relate to its high cost and consequent lack of
access in many centres, need for optimisation of workflow and image acquisition parame‐
ters, and a greater body of evidence to evaluate its perceived superiority over existing tech‐
niques in neurooncology such as PET/CT, MRI or indeed PET/CT and MRI with software
fusion of PET and MRI data. This would presumably require the results of large randomised
controlled trials that should be a focus of future research efforts.
12. Conclusion
Whilst MRI remains the gold standard for imaging of brain tumours, future applications in‐
tegrating PET—with its enlarging gamut of radiotracers—and MRI are likely forthcoming.
This chapter briefly summarised the current status of the most commonly used radiotracers
for the molecular imaging of brain tumours (Table 2). It will hopefully also serve as a useful
guide that the reader can refer back to and build upon with future reading.
Radiotracer Mechanism Advantages Disadvantages
FDG Glucose analogue, active transport
into cell mediated by GLUT
transport proteins; phosphorylated
by hexokinase and trapped
intracellularly
Most widely used and explored
radiotracer in PET
Poor tumour-to-background
contrast due to intense
physiological uptake in
normal brain
MET Essential amino acid transported
into malignant glioma cells by
LAT1 transporter and incorporated
into proteins
Generally regarded as reference in
glioma diagnosis, grading, prognosis,
imaged-guided biopsy and
Short half-life (20 min) due
to C-11 radiolabelling limits
use to centres with cyclotron
on-site or very nearby
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Radiotracer Mechanism Advantages Disadvantages
radiotherapy planning, and detection
of tumour recurrence in PET
FET Artificial amino acid transported
into upregulated glioma cells but
not incorporated into proteins
Overall accuracy for diagnosis of
glioma comparable to MET; can
distinguish active tumour from
radiation necrosis; late phase FET PET
may be useful for grading
meningiomas
Use in grading of gliomas
requires dynamic analysis of
activity over time since not
incorporated into proteins
FDOPA Fluorinated form of L-DOPA, the
precursor of dopamine that is
transported physiologically into
brain and abnormally (increased)
into glioma
Uptake correlates with tumour
proliferation and grade; more accurate
than FDG for evaluating low-grade
tumours and distinguishing tumour
recurrence from radiation necrosis
Limited data outside of use
for initial diagnosis of glioma
FLT Thymidine analogue and substrate
for cellular thymidine kinase 1 but
poor substrate for mitochondrial
thymidine kinase 2
More sensitive than FDG for detection
of recurrent high-grade glioma;
correlates better with tumour
progression and survival
May accumulate in benign
brain lesions with disrupted
blood–brain barrier
Choline Water-soluble B-complex vitamin
phosphorylated and subsequently
integrated into lecithin, a
component of cell membrane
phospholipids
Can be radiolabelled with C-11 and
F-18; higher uptake generally
corresponds with higher grade; more
accurate than FDG for distinguishing
tumour recurrence from radiation
necrosis
May accumulate in benign
inflammatory lesions
FMISO First-generation nitroimidazole;
enters cells by diffusion and
subsequently reduced at a rate
inversely proportional to oxygen
tension
Permits quantification of hypoxia
which has been shown to predict
worse prognosis; can differentiate low
from high grade gliomas
Requires venous blood
sampling for quantification
of hypoxia
FAZA Second-generation nitroimidazole Better hypoxia-to-normoxia contrast
than FMISO
Requires venous blood
sampling for quantification
of hypoxia
Somatostatin
analogues
Bind with high affinity to
somatostatin receptors expressed
richly by neuroendocrine tumours
and some non-neuroendocrine
tumours including meningiomas
Excellent tumour-to-background
contrast for neuroendocrine tumours;
appears promising for tumour
delineation in radiotherapy planning
Limited data for use in
radiotherapy planning
Table 2. Summary of radiotracers most commonly used in PET imaging of brain tumours.
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